Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 12.86
- Piotroski Score 3.00
- Grade Buy
- Symbol (VRDN)
- Company Viridian Therapeutics, Inc.
- Price $19.92
- Changes Percentage (1.5%)
- Change $0.3
- Day Low $19.44
- Day High $20.01
- Year High $27.20
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/25/2025
- Fiscal Year End N/A
- Average Stock Price Target $39.50
- High Stock Price Target $56.00
- Low Stock Price Target $22.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$4.49
- Trailing P/E Ratio -2.71
- Forward P/E Ratio -2.71
- P/E Growth -2.71
- Net Income $-237,734,000
Income Statement
Quarterly
Annual
Latest News of VRDN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Viridian Therapeutics, Inc. (VRDN) Stock Price, News, Quote & History
Viridian Therapeutics is a biotech company specializing in treatments for rare diseases. Their pipeline includes VRDN-001 and VRDN-003 for thyroid eye disease, and VRDN-006 for autoimmune diseases. Fo...
By Yahoo! Finance | 3 months ago -
Are Analysts Bullish on Viridian Therapeutics, Inc. (VRDN) Right Now?
A list of top small-cap stocks with high potential was compiled. Viridian Therapeutics, Inc. (NASDAQ:VRDN) stands out with its promising products for autoimmune diseases. Analysts forecast a significa...
By Yahoo! Finance | 4 months ago
